H.C. Wainwright analyst Robert Burns raised the firm’s price target on Revolution Medicines (RVMD) to $73 from $72 and keeps a Buy rating on ...

Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated ...

The future of Revolution Medicines hinges largely on the success of its clinical trials and the potential approval and commercialization of its drug candidates. Key catalysts to watch include: 1.

Revolution Medicines, Inc. (NASDAQ:RVMD), a biotechnology company focused on developing novel therapies for cancer, has been making significant strides in its clinical pipeline, particularly in ...

REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with ...

Short interest in Revolution Medicines Inc (NASDAQ:RVMD) decreased during the last reporting period, falling from 16.59M to 15.91M. This put 9.12% of the company's publicly available shares short.